Figure 5. Dasatinib targets immature and germinal center B cells.
B6.CD45.1 mice repopulated with bone marrow cells from a c-CblA/− mouse were dosed twice daily with 15 mg/kg of dasatinib for 16 days. WBCs and spleen cells were analyzed by flow cytometry to identify B cell populations that are most sensitive to dasatinib. Shown are representative flow cytometry profiles and data from 3 vehicle and 3 dasatinib treated mice. (A) B220+ WBCs and (B) B220+ spleen cells were analyzed for the expression of IgM and IgD to identify immature and mature B cells. The gates show immature IgM+ IgD− B cells. (C) B220+ spleen cells analyzed for the expression of GL7 and CD95 to identify germinal center (GC) B cells. The results are expressed as means ± standard errors. *P<0.05, **P<0.01 using the unpaired Student’s t test.